SRR650192
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V2+0.570
- MYC_TARGETS_V1+0.530
- INTERFERON_ALPHA_RESPONSE+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.320
- MITOTIC_SPINDLE+0.290
- PI3K_AKT_MTOR_SIGNALING+0.240
- INTERFERON_GAMMA_RESPONSE+0.210
- DNA_REPAIR+0.190
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.590
- COAGULATION-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- XENOBIOTIC_METABOLISM-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- BILE_ACID_METABOLISM-0.420
- CHOLESTEROL_HOMEOSTASIS-0.380
- MYOGENESIS-0.380
- UV_RESPONSE_DN-0.370
- ADIPOGENESIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53536_S130 | — | cohortSQ1 | 0.873 |
| 2 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.844 |
| 3 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.844 |
| 4 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.843 |
| 5 | SRR650180 | — | — | 0.838 |
| 6 | SRR33532781 | — | D | 0.838 |
| 7 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.836 |
| 8 | TCGA-D8-A147-01A-11R-A115-07 | — | E | 0.829 |
| 9 | TCGA-90-7766-01A-21R-2125-07 | — | cohortSQ1 | 0.827 |
| 10 | SRR8518219 | — | E | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |